The Vitreomacular Interface in Diabetic Retinopathy
Diabetic retinopathy (DR) is a leading health concern and a major cause of blindness. DR can be complicated by scar tissue formation, macular edema, and tractional retinal detachment. Optical coherence tomography has found that patients with DR often have diffuse retinal thickening, cystoid macular...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2015/392983 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832568080487677952 |
---|---|
author | Daniel Agarwal Rachel Gelman Claudia Prospero Ponce William Stevenson John B. Christoforidis |
author_facet | Daniel Agarwal Rachel Gelman Claudia Prospero Ponce William Stevenson John B. Christoforidis |
author_sort | Daniel Agarwal |
collection | DOAJ |
description | Diabetic retinopathy (DR) is a leading health concern and a major cause of blindness. DR can be complicated by scar tissue formation, macular edema, and tractional retinal detachment. Optical coherence tomography has found that patients with DR often have diffuse retinal thickening, cystoid macular edema, posterior hyaloid traction, and tractional retinal detachment. Newer imaging techniques can even detect fine tangential folds and serous macular detachment. The interplay of the vitreous and the retina in the progression of DR involves multiple chemokine and other regulatory factors including VEGF. Understanding the cells infiltrating pathologic membranes at the vitreomacular interface has opened up the possibility of new targets for pharmacotherapy. Vitrectomies for DR remain a vital tool to help relieve tension on the macula by removing membranes, improving edema absorption, and eliminating the scaffold for new membrane formation. Newer treatments such as triamcinolone acetonide and VEGF inhibitors have become essential as a rapid way to control DR at the vitreomacular interface, improve macular edema, and reduce retinal neovascularization. These treatments alone, and in conjunction with PRP, help to prevent worsening of the VMI in patients with DR. |
format | Article |
id | doaj-art-667201a431604289936342d33894b403 |
institution | Kabale University |
issn | 2090-004X 2090-0058 |
language | English |
publishDate | 2015-01-01 |
publisher | Wiley |
record_format | Article |
series | Journal of Ophthalmology |
spelling | doaj-art-667201a431604289936342d33894b4032025-02-03T00:59:50ZengWileyJournal of Ophthalmology2090-004X2090-00582015-01-01201510.1155/2015/392983392983The Vitreomacular Interface in Diabetic RetinopathyDaniel Agarwal0Rachel Gelman1Claudia Prospero Ponce2William Stevenson3John B. Christoforidis4Department of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADepartment of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADepartment of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADepartment of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADepartment of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADiabetic retinopathy (DR) is a leading health concern and a major cause of blindness. DR can be complicated by scar tissue formation, macular edema, and tractional retinal detachment. Optical coherence tomography has found that patients with DR often have diffuse retinal thickening, cystoid macular edema, posterior hyaloid traction, and tractional retinal detachment. Newer imaging techniques can even detect fine tangential folds and serous macular detachment. The interplay of the vitreous and the retina in the progression of DR involves multiple chemokine and other regulatory factors including VEGF. Understanding the cells infiltrating pathologic membranes at the vitreomacular interface has opened up the possibility of new targets for pharmacotherapy. Vitrectomies for DR remain a vital tool to help relieve tension on the macula by removing membranes, improving edema absorption, and eliminating the scaffold for new membrane formation. Newer treatments such as triamcinolone acetonide and VEGF inhibitors have become essential as a rapid way to control DR at the vitreomacular interface, improve macular edema, and reduce retinal neovascularization. These treatments alone, and in conjunction with PRP, help to prevent worsening of the VMI in patients with DR.http://dx.doi.org/10.1155/2015/392983 |
spellingShingle | Daniel Agarwal Rachel Gelman Claudia Prospero Ponce William Stevenson John B. Christoforidis The Vitreomacular Interface in Diabetic Retinopathy Journal of Ophthalmology |
title | The Vitreomacular Interface in Diabetic Retinopathy |
title_full | The Vitreomacular Interface in Diabetic Retinopathy |
title_fullStr | The Vitreomacular Interface in Diabetic Retinopathy |
title_full_unstemmed | The Vitreomacular Interface in Diabetic Retinopathy |
title_short | The Vitreomacular Interface in Diabetic Retinopathy |
title_sort | vitreomacular interface in diabetic retinopathy |
url | http://dx.doi.org/10.1155/2015/392983 |
work_keys_str_mv | AT danielagarwal thevitreomacularinterfaceindiabeticretinopathy AT rachelgelman thevitreomacularinterfaceindiabeticretinopathy AT claudiaprosperoponce thevitreomacularinterfaceindiabeticretinopathy AT williamstevenson thevitreomacularinterfaceindiabeticretinopathy AT johnbchristoforidis thevitreomacularinterfaceindiabeticretinopathy AT danielagarwal vitreomacularinterfaceindiabeticretinopathy AT rachelgelman vitreomacularinterfaceindiabeticretinopathy AT claudiaprosperoponce vitreomacularinterfaceindiabeticretinopathy AT williamstevenson vitreomacularinterfaceindiabeticretinopathy AT johnbchristoforidis vitreomacularinterfaceindiabeticretinopathy |